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Abstract
Background: The Institute of Medicine has called for approaches to help maximize 
the return on investments (ROI) in cancer clinical trials. Value of Research (VOR) is 
a health economics technique that estimates ROI and can inform research prioritiza-
tion. Our objective was to evaluate the impact of using VOR analyses on the clinical 
trial proposal review process within the SWOG cancer clinical trials consortium.
Methods: We used a previously developed minimal modeling approach to calculate 
VOR estimates for 9 phase II/III SWOG proposals between February 2015 and 
December 2016. Estimates were presented to executive committee (EC) members 
(N = 12) who determine which studies are sent to the National Cancer Institute for 
funding consideration. EC members scored proposals from 1 (best) to 5 based on 
scientific merit and potential impact before and after receiving VOR estimates. EC 
members were surveyed to assess research priorities, proposal evaluation process 
satisfaction, and the VOR process.
Results: Value of Research estimates ranged from −$2.1B to $16.46B per proposal. 
Following review of VOR results, the EC changed their score for eight of nine pro-
posals. Proposal rankings were different in pre- vs postscores (P value: 0.03). 
Respondents had mixed views of the ultimate utility of VOR for their decisions with 
most supporting (42%) or neutral (41%) to the idea of adding VOR to the evaluation 
process.
Conclusions: The findings from this pilot study indicate use of VOR analyses may 
be a useful adjunct to inform proposal reviews within NCI Cooperative Clinical 
Trials groups.
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1 |  INTRODUCTION
The National Academy of Medicine (formerly the Institute 
of Medicine has called for approaches to help maximize the 
return on research investments in cancer clinical trials, stating 
that, “prioritization and selection of trial concepts is critical 
to ensure that limited public funds are used in ways that are 
likely to have the greatest impact on patient care.”1 Value of 
Research (VOR; also known as Value of Information, VOI) 
analysis is a health economics technique that estimates the 
clinical and economic returns for research investments.2-7 
Specifically, VOR estimates the value of reducing treatment 
decision uncertainty, by comparing the evidence that exists 
for a therapy today vs the aggregated evidence generated by 
collecting additional information (eg, through a clinical trial). 
This estimate of the potential reduction in evidence uncer-
tainty can inform policymakers of the sufficiency of current 
evidence to adopt a new therapy, as well as the remaining 
risk of prematurely making a “wrong” decision. Cancer clin-
ical trials groups, with an abundance of testable and poten-
tially impactful research ideas, coupled with their reliance 
on constrained public budgets, are an ideal testing ground to 
evaluate the addition of VOR estimates to their research pri-
oritization processes.
As an example, consider the information available from 
a small clinical trial for a given cancer drug, with a modest 
treatment effect and a wide confidence interval given the lim-
ited size of the study population. If clinicians were to make 
treatment decisions based on this small trial, the probabil-
ity that they would be making the optimal decision might 
be fairly low. By conducting an analogous, larger trial, with 
smaller confidence intervals for each outcome, the impact of 
the drug on the outcome and the uncertainty about the result 
falls substantially, thus our chances of making a correct treat-
ment decision is increased—regardless of whether the trial 
is “positive” or “negative.” VOR analysis captures the value 
of the additional research by estimating the likely future im-
pacts on patient outcomes and healthcare resources using 
economic theory and decision modeling techniques. VOR 
is particularly useful in prioritizing research when it can be 
applied in decision- relevant time frame, can be customized 
to individual decision- making groups, and produces a metric 
that is comparable across analyses; all else being equal, the 
research proposals with the highest VOR should be priori-
tized over others.7-10
In the context of VOR, the economic value of a clinical 
trial is a function of four key elements: (a) the current level 
of decision uncertainty (ie, the probability that we are mak-
ing suboptimal decisions based on current knowledge), (b) 
the scale and scope of new information to be collected in the 
trial, (c) the consequences of making a suboptimal decision in 
terms of a patient’s life expectancy, quality of life, or health-
care costs, and (d) the number of future patients likely to face 
the decision. VOR for a particular study will be high when 
there is substantial uncertainty about the decision, the clin-
ical and/or economic consequences of making a suboptimal 
choice are significant, and/or the affected population is large.
Although the theory and basic methodology of VOR 
analysis have been described for several years, practical use 
of VOR in real- world research decision settings has been 
limited. Accordingly, we engaged with SWOG, a large can-
cer clinical trials network, to develop a cooperative group, 
clinical trial- oriented process for integrating VOR estimates 
into the research prioritization process. The objectives of 
our study were to evaluate the impact of VOR estimates on 
the decisions made by SWOG’s executive review committee 
(EC) and evaluate their opinions about VOR and its useful-
ness for their decision- making criteria.
2 |  METHODS
2.1 | Setting
This work was conducted as part of a Patient- Centered 
Outcomes Research Institute (PCORI) funded project eval-
uating a structured approach to prioritizing cancer research 
using stakeholders and VOR within SWOG, one of four NCI- 
sponsored clinical trials networks (NCTN). SWOG research 
studies are proposed and developed by members from com-
mittees (eg, lung, breast cancer) and, after approval by the 
organ- based committee, study proposals are sent to SWOG’s 
Executive Review Committee (EC) for an internal review. 
EC members assign a prioritization score to proposals after 
presentation by the study lead investigators. While the estab-
lished evaluation and scoring process considers a large num-
ber of factors, EC members are asked to specifically address 
the following issues: (a) the scientific strength and feasibility 
of the proposal; (b) potential overlap with actively recruiting 
SWOG studies that might pose threats to accrual; (c) whether 
the study leverages other research currently being conducted 
in NCI- supported cancer centers; and (d) potential future im-
pact on cancer patient care and outcomes irrespective of the 
outcome of the study (ie, “positive” or “negative”). Highly 
scored proposals are sent to the Cancer Treatment Evaluation 
Program at the NCI. Lower score proposals are returned to 
the investigator for revisions, or are rejected for further de-
velopment. Our study focused on phase II and III randomized 
studies from the breast, genitourinary (GU), gastrointestinal 
(GI), and cancer care delivery (CCD) committees.
2.2 | Stakeholder training in VOR
Our process included training in VOR theory and methods. 
We engaged SWOG members from the EC and the included 
disease committees (approximately 200 total participants) 
in an iterative and multifaceted manner using in- person 
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meetings, web- enabled teleconferences, and web- based edu-
cational materials to provide training in VOR and actively 
solicit their preferences and feedback (see VOR educational 
materials in the Supplemental materials). Our goals were to 
create shared understanding of VOR methods and develop a 
transparent and SWOG- specific process for generating and 
presenting VOR estimates as part of SWOG’s proposal eval-
uation process.11
2.3 | Generating and presenting VOR 
estimates for study concepts
Our approach involved integration of VOR without undue 
burden on SWOG processes and timelines (Figure 1). After 
receipt of a proposal, we used a previously developed minimal 
modeling approach to calculate per- patient and population- 
level (based on US cancer incidence) VOR estimates.8 We 
estimated the level of uncertainty regarding the proposed 
trial using either expert elicitation or historical data. These 
approaches are described in more detail in a supplementary 
methods section (Appendix S1). We also performed a vali-
dation step in which we contacted the proposal’s principal 
investigator to review the model inputs. We then developed a 
final model, generated, and presented full VOR results with 
details on the model structure, inputs, and VOR estimates.
The VOR estimates were provided in both disaggregated 
(ie, the expected clinical and economic impacts separately) and 
aggregated forms based on feedback during the development 
phase of the project. The aggregated forms included the de-
velopment and use of clinical VOR (ie, VOR based solely on 
the expected clinical benefit), and comprehensive VOR (ie, 
VOR estimates based on expected clinical and economic im-
pacts). The clinical and comprehensive VOR estimates were 
specific to the clinical study evaluated and used the expected 
value of sample information approach.12
2.4 | Study sample
The prospective VOR evaluation phase was conducted from 
February 2015 to December 2016. A total of 10 studies met 
our initial criteria of randomized phase II or III studies from 
an included disease committee. One study was not reviewed 
by the EC due to external logistical factors for the study; thus 
nine studies were evaluated, presented, and scored (Table 1). 
EC committee members were provided access to training ma-
terials about VOR and our processes prior to (or during in the 
case of new members) the prospective evaluation phase.
2.5 | Value of research (VOR) calculations
We estimated the expected VOR using Bayesian decision 
theoretic methods. Our methods have been described previ-
ously,8 but briefly, we (a) created a minimal decision model 
using a simple Markov model framework; (b) populated the 
model with data from the clinical trial proposal and external 
data sources; (c) characterized the level of current uncertainty 
F I G U R E  1  A Graphic Representation of the Process we used to Integrate VOR Analyses into SWOG’s Proposal Evaluation Procedures
4254 |   CARLSON et AL.
including the prior distribution of the treatment effect; (d) 
simulated the range of expected trial results using the cur-
rent level of uncertainty and the trial’s planned sample size 
and length of follow- up; (e) compared the expected quality- 
adjusted life years (QALYs) gained and healthcare costs of 
decisions made with the additional evidence from the pro-
posed trial to those made with only existing evidence; and 
(f) estimated the size of the relevant patient population ex-
pected to face the treatment decision using the Surveillance, 
Epidemiology, and End Results (SEER) database and pub-
lished literature. Analyses were performed in Microsoft 
Excel© or R.13 We assumed a time horizon of 10- years for 
the information being generated in each trial to be decision- 
relevant.14,15 We also used a 3% discount rate for future costs 
and benefits, and accounted for the delay in the availability 
of information by including the accrual rates and specified 
follow- up time in the trial proposals.16
2.6 | Minimal modeling framework
We developed and used a Markov model framework using 
the trial proposal’s primary endpoint. This framework con-
sisted of up to three health states: (a) alive, preprimary end-
point, (b) alive, postprimary endpoint, and (c) death, and 
was informed by work by Meltzer and Basu and has been 
described previously.8,10 This modeling framework is consid-
ered sufficient and appropriate for the research prioritization 
context given the need for timely model development and 
the availability well- developed study capsules that include 
evidence and expert opinion to empirically characterize the 
relationship between the trial’s primary endpoint and a com-
prehensive measure of health outcomes.8,10 We estimated 
the probability of transitioning from preprimary endpoint to 
postprimary endpoint for the control arm from the survival 
parameters included in the trial proposal and assuming a con-
stant failure rate (ie, an exponential distribution). This is in 
line with the assumptions used in the trial proposal’s sample 
size calculations.
2.7 | Executive review committee evaluation 
regarding opinions of VOR for decision making
Executive committee members scored proposals before and 
after receiving the full set of VOR estimates including the ex-
pected incremental QALYs and costs, the clinical VOR, and 
the comprehensive VOR, during SWOG’s regularly scheduled 
proposal review meetings. Scores ranged from 1 (best) to 5.
To evaluate EC member’s opinions about their experience 
with VOR we surveyed members at baseline and again at 
study end (Appendix S2: EC surveys). The surveys were in-
formed by targeted telephone interviews with SWOG staff and 
EC members coupled with previous work evaluating stake-
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questions about research priorities during proposal evaluation 
and satisfaction with the current proposal evaluation process. 
The end- of- study survey also included additional questions 
about the VOR process. Survey participants were contacted 
via email and provided a link to the web- based survey.
2.8 | Data analysis
The primary outcomes were the EC proposal score and pro-
posal ranking before and after viewing the VOR results. In 
secondary analysis, we evaluated the association between 
the per patient and population- level VOR estimates and 
the change in scores. For both these analyses, we used the 
Wilcoxon signed- rank test, which is a nonparametric sta-
tistical hypothesis test used for comparing repeated meas-
urements to determine whether the population mean ranks 
differ.
We analyzed the survey results using descriptive statis-
tics. For the subset of questions and respondents for whom 
we had baseline and postsurvey results, we evaluated the 
change in respondent answers about the importance of sev-
eral decision- making factors using the Wilcoxon signed- 
rank test. All statistical tests were two- sided using an alpha 
level of 0.05.
3 |  RESULTS
Among the nine studies evaluated, six were phase II and three 
were phase III, target sample sizes ranged from 60 to 1000, 
and the disease areas involved were breast (3), colorectal (2), 
gastric (1), pancreatic (1), bladder (1), and cancer of unknown 
primary (1). The VOR results (Table 1, Figures 2 and 3) 
show that the population clinical VOR estimates ranged from 
F I G U R E  2  The VOR Estimates 
for each Proposal at the per Patient 
and Population Level and Using the 
Comprehensive and Clinical VOR Metrics
F I G U R E  3  The Executive Committee 
Proposal Scores Pre- and Postreceiving the 
VOR Estimates. The Capsule Rankings were 
Different in the Pre vs Postscores, Implying 
that a Different set of Capsules may have 
been Prioritized Under a Fixed Budget
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$0.13B to $16.53B and the comprehensive VOR estimates 
ranged from −$2.1B to $16.46B. The EC proposal scores 
changed for eight of nine proposals following presentation of 
VOR results. Proposal rankings were significantly different 
in the pre- vs postscores (P value: 0.03). The scores for six 
of the nine proposals changed in the direction of the compre-
hensive VOR estimate (ie, the score went down indicating a 
higher rank, when the VOR was positive indicating a positive 
return on investment), one did not change and two moved 
in the opposite direction. However, there was no significant 
association between comprehensive VOR estimates and the 
magnitude of the change in proposal scores (P > 0.05). We 
did not find an association between the direction or the mag-
nitude of the VOR estimates and the direction or magnitude 
of the proposal score change (all P > 0.1).
3.1 | EC survey results
At baseline 11 of 16 EC members consented to and com-
pleted the baseline survey. At study end, there were 15 EC 
members (four were no longer on the EC and three added) 
12 of which completed the follow- up survey. Two did not 
consent and one was excluded due to her role as a study co- 
investigator. Nine respondents completed both baseline and 
end- of- study surveys. Pooled respondent characteristics are 
provided in Table 2.
There was a general trend toward decreased average rat-
ings of importance for most of the listed factors; ratings for 
economic value increased (Table 3). The results of the post-
study survey are provided in Table 4 and Table 5. Sixty- seven 
percent of respondents rated their knowledge about VOR 
as moderate or high at study end vs 0% prior to this study. 
Seventy- five percent felt confident interpreting VOR data.
Respondents had mixed views of the ultimate utility of 
VOR for their decisions but were mostly positive. Two- thirds 
felt that the training was sufficient and that the VOR material 
was easy to understand. The majority (91%) felt that the VOR 
material provided to EC was appropriate in length. Most re-
spondents either agreed (50%) or were neutral (42%) about 
whether the VOR proposal evaluation aided their decision 
making or helped the evaluation process. Forty two percent 
support adding VOR to the evaluation process with 41% neu-
tral and 17% disagreeing.
4 |  DISCUSSION
As an experiment to aid decision making about clinical 
trial research prioritization, we developed and imple-
mented a VOR evaluation process for SWOG, a large 
NCI- sponsored cancer clinical trials cooperative research 
group. The process involved rapid development of VOR 
models based on the clinical trial research proposal, 
published literature, and expert elicitation followed by 
model validation. The content and format of the VOR re-
sults were developed with input from SWOG members. 
The results impacted scores for eight out of nine study 
proposals. While the implementation of the VOR process 
was feasible, EC members had mixed acceptance of the 
idea of integrating VOR into the proposal evaluation pro-
cess: roughly half viewed it favorably and the remainder 
were neutral or opposed.
To our knowledge, this is the first study to develop pro-
cesses for incorporating VOR methods and results into an 
established clinical trials prioritization review process in the 
United States. Encouragingly, we found that the clinicians 
who design and implement clinical trials readily grasped 
the concept of VOR and the implications of VOR for trial 
concept proposals during their weekly review and rating ses-
sions. In addition, it was feasible to generate VOR results in 
the generally short window between the time when of trial 
proposal completes final statistical review after leaving the 
disease committee and the time it was reviewed by the EC. 
The VOR results often negatively impacted the proposal 
rankings, likely because the estimated return on investment 
was small or negative in many cases. Even though the scores 
changed following presentation of the VOR results, the in-
formation did not materially change the EC recommendation 
from an “approve” to “reject” decision (or vice versa) for any 
proposal in this study.
Although there was general acceptance of the VOR meth-
odology and appreciation of its potential value for decision 
making, the study investigator team did find ongoing resis-
tance to VOR from a minority of investigators, as well as con-
cerns at the outset that required modification of the approach. 
An early complaint was that investigators were being unfairly 
“punished” in the comprehensive VOR results because of the 
very high cost of the drugs that were frequently being evaluated 
T A B L E  2  Executive review committee characteristics
Professional experience
Mean years (SD) in SWOG 17.9 (4.9)






 Breast cancer 35%
 Genitourinary cancer 17%
 Hematologic malignancies 13%
 Radiation oncology 9%
 Other 26%
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in the trials they were designing. These high- cost drugs were 
often the primary factor causing negative VOR estimates, that 
is, the value of the expected clinical benefit from a trial was 
less than the expected costs needed to generate the benefits at 
commonly used thresholds of societal value (ie, $150 000 per 
QALY).18 The investigators’ argument was that understanding 
Pre/postanalysis
Baseline 
(n = 9) 
Mean
End of study 




Feasibility 6.56 5.78 −0.78 0.056
Clinical importance 6.33 5.89 −0.44 0.164
Scientific 
contribution
6.00 6.00 0.00 1
Relative resource use 4.89 5.00 0.11 0.95
Economic value 3.78 4.78 1.00 0.0168
Disease burden 4.44 4.22 −0.22 0.157
Current uncertainty 4.89 4.56 −0.33 0.472
Applicability to 
clinical practice
6.00 6.11 0.11 0.655
Timeliness 5.67 5.78 0.11 0.706
Suitability for 
SWOG
6.11 5.78 −0.33 0.083
Role of NCI 4.56 4.56 0.00 1
VOR N/A 5.00 N/A N/A
*Paired T test
T A B L E  3  Results of the Executive 
Review Committee survey pre/postanalysis
T A B L E  4  Results of the Executive Review Committee end- of- study survey on the VOR experience
Experience of the VOR process (n = 12)
Moderate/High, % Low/No, %
Prior knowledge of VOR 0 100
Postknowledge of VOR 67 33
Confidence in interpreting VOR 75 25
(Somewhat) agree, % Neither agree nor disagree, %
(Somewhat) 
disagree, %
The team addressed my input before 
incorporating VOR
27 46 27
Training in VOR was sufficient 67 25 8
VOR material provided to EC was easy 
to understand
67 16 17
VOR material provided to EC was 
appropriate in length
91 9 0
The VOR proposal evaluation aided my 
decision making
50 42 8
The VOR materials helped the evaluation 
process
50 42 8
The VOR materials hindered the 
evaluation process
8 42 50
I support adding VOR to the proposal 
evaluation process
42 41 17
The results of the Executive Review Committee end- of- study survey. The questionnaire is provided in the Supplementary materials. The questions used a Likert scale.
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the clinical impact of the drugs superseded the economic im-
pact, and that the cost of the drugs was out of their control and 
changing over time. In response, the research team created a 
“clinical VOR” result that excluded treatment costs. This issue 
would also suggest that our VOR educational materials should 
include more information about opportunity costs, especially 
in the context of high- cost treatments.
The investigators also raised the concern that trials ad-
dressing treatments for uncommon cancers were unfairly 
disadvantaged compared to trials for more common can-
cers. In response, the investigator team presented VOR es-
timates for the average patient (in addition to population 
level) to allow comparisons independent of the size of the 
overall patient population. The intent of these changes was 
to create a VOR process that informed SWOG’s decision- 
makers and their VOR preference heterogeneity. Even with 
these modifications, a few EC members did not participate 
in the VOR training or evaluation components of the study. 
It is unclear whether this was due to lack of interest or 
actual resistance to the concept and approach. This resis-
tance was reflected in the responses to two end- of- study 
survey study questions; 8% of respondents stated that the 
VOR materials hindered the evaluation process and 17% 
disagreed with a question asking about support for adding 
VOR to the proposal evaluation process. This reinforces 
the need for early engagement with the research organiza-
tion and efficiency in the integration process to decrease 
undue burden.
Prior work by ourselves and other U.S. researchers eval-
uated VOR with healthcare stakeholders, but the evaluation 
took place outside of a specific decision- making process.7,9 
Outside of the US, Claxton and Sculpher identified similar 
challenges to those that we encountered in a pilot study that 
applied VOR to inform policy decisions about research pri-
orities in the United Kingdom.4 In general, the committees 
involved in reviewing the studies found that VOR results 
were “interesting and potentially useful,” although they did 
not have an impact on the decisions taken. Unfamiliarity with 
the methods was cited as an issue, as well as some question-
ing the quality and relevance of the models.4 Our findings 
are similar to past studies in that the barriers to adoption of 
VOR- informed research prioritization are primarily cultural 
instead of technical.19
Our study has limitations which warrant consideration. 
The clinical experts within SWOG had difficulty providing 
estimates of the current uncertainty about the proposed treat-
ment decision to be evaluated in the given protocol. To address 
this, we developed an expert elicitation survey and an alterna-
tive option based on historical data about how often SWOG 
trials met their study endpoints. To reduce the potential bias 
due to optimistic estimates in favor of the new interventions, 
the survey was provided to the entire disease committee, 
rather than just the proposal development team and included 
data about historical norms, that is, “Data from a review of 
cooperative group clinical trials from 1955 to 2006 indicate 
that these values are 60% and 25% on average, respectively.” 
T A B L E  5  Results of the Executive Review Committee end- of- study survey: importance of factors related to decision making
Importance of factors in decision making (n = 12)
Not at all 
important, 
% Very low, % Slightly, % Somewhat, % Moderately, % Very, % Extremely, %
Feasibility 0 0 0 9 4 52 35
Clinical importance 0 0 0 9 17 43 31
Scientific 
contribution
0 0 0 9 18 55 18
Relative resource 
use
0 0 9 13 61 17 0
Economic value 0 9 22 17 35 17 0
Disease burden 0 0 18 39 30 13 0
Current uncertainty 0 0 9 22 56 4 9
Applicability to 
clinical practice
0 0 0 5 18 50 27
Timeliness 0 0 0 9 26 56 9
Suitability for 
SWOG
0 0 0 9 9 61 21
Role of NCI 0 9 13 13 52 13 0
VOR (post only) 0 0 9 9 55 27 0
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Our study was also limited by the number of proposals that 
were evaluated by the SWOG EC during the prospective eval-
uation period. Our evaluation was limited to phase II and III 
studies that had comparator arms. Uncontrolled studies have 
value, but our minimal model VOR approach cannot easily 
accommodate these study designs. We were also limited to 
average executive committee scores due to the anonymous 
nature of the SWOG voting process, thus we were not able 
to evaluate individual- level impacts. Finally, changes in the 
composition of the EC hindered our pre/post evaluations and 
thus limited our ability to assess changes in attitudes toward 
VOR over time.
There are number of potential areas for future research 
about the role and use of VOR in research prioritization. One 
such area would be to investigate the best methods for estab-
lishing estimates of the current uncertainty using expert elic-
itation or other methods. Another area is the potential impact 
of VOR later in the proposal evaluation process, that is, at the 
NCI level, where the final funding decision is made. Future 
researchers may wish to take the lessons gleaned from this 
study to determine whether VOR be feasible and acceptable 
in other cancer cooperative groups or other clinical trial set-
tings in different disease areas.
In summary, we developed and implemented a VOR 
evaluation process for clinical trial proposals being de-
veloped for SWOG using collaborative engagement and 
an efficient minimal modeling approach. The process was 
feasible in a decision- relevant time frame, impacted scores, 
and EC member opinions were mixed but mostly favorable. 
SWOG leaders currently consider a number of factors in 
research prioritization such as scientific validity, study fea-
sibility, and potential impact on patients and patient care. 
We view VOR as complementary to these considerations, 
as well as providing a quantitative estimate that can help 
understand the impact of the study on cancer care decisions 
and outcomes. In line with previous work on this topic, en-
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